Kalaris Therapeutics, Inc.
KLRS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001754068
No open-market purchases or sales by Kalaris Therapeutics, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $73.4M in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Kalaris Therapeutics, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 32
- +2 vs. Q2 2025
- Shares held
- 13.2M
- −139.4K (−1.0%) vs. Q2 2025
- Total value
- $76.4M
- +$40.8M (+114.2%) vs. Q2 2025
- New holders
- 8
- 9 more added
- Sold out
- 6
- 5 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KLRS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 56 | $73.4M |
| Q1 2026 | 58 | $107.2M |
| Q4 2025 | 51 | $151.9M |
| Q3 2025 | 32 | $76.4M |
| Q2 2025 | 30 | $35.7M |
| Q1 2025 | 32 | $111.4M |
| Q4 2024 | 53 | $20.7M |
| Q3 2024 | 60 | $36.3M |
| Q2 2024 | 72 | $33.9M |
| Q1 2024 | 77 | $36.4M |
| Q4 2023 | 82 | $28.5M |
| Q3 2023 | 90 | $115.5M |
| Q2 2023 | 94 | $183.6M |
| Q1 2023 | 89 | $156.0M |
| Q4 2022 | 86 | $193.1M |
| Q3 2022 | 87 | $293.7M |
| Q2 2022 | 84 | $109.6M |
| Q1 2022 | 84 | $184.1M |
| Q4 2021 | 84 | $329.4M |
| Q3 2021 | 80 | $640.3M |
| Q2 2021 | 84 | $521.8M |
| Q1 2021 | 75 | $624.4M |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Kalaris Therapeutics, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 85 | $0 | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 1 | $6 | 0.00% | +1 | New |
| SBI Securities Co., Ltd. | 8 | $46 | 0.00% | −2−20.0% | Reduced |
| Farther Finance Advisors, LLC | 33 | $191 | 0.00% | 00.0% | Unchanged |
| Parallel Advisors, LLC | 49 | $283 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 50 | $289 | 0.00% | 00.0% | Unchanged |
| BNP Paribas Arbitrage, SA | 141 | $815 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 217 | $1.25K | 0.00% | −56−20.5% | Reduced |
| Strengthening Families & Communities, LLC | 268 | $1.55K | 0.00% | +268 | New |
| Federated Hermes, Inc. | 578 | $3.34K | 0.00% | −56−8.8% | Reduced |
| UBS Group AG | 5,252 | $30.4K | 0.00% | +1,136+27.6% | Added |
| FMR LLC | 7,806 | $45.1K | 0.00% | 00.0% | Unchanged |
| Johnson Financial Group, Inc. | 10,000 | $57.8K | 0.00% | +10,000 | New |
| Marshall Wace, LLP | 14,115 | $81.6K | 0.00% | 00.0% | Unchanged |
| RBF Capital, LLC | 17,391 | $100.5K | 0.00% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 22,465 | $129.8K | 0.00% | +22,465 | New |
| Bridgeway Capital Management, LLC | 22,500 | $130.1K | 0.00% | +22,500 | New |
| State Street Corp | 22,610 | $130.7K | 0.00% | +11,900+111.1% | Added |
| Morgan Stanley | 24,918 | $144.0K | 0.00% | +22,954+1,168.7% | Added |
| Millennium Management LLC | 24,923 | $144.1K | 0.00% | −29,169−53.9% | Reduced |
| Belpointe Asset Management LLC | 40,000 | $231.2K | 0.01% | +40,000 | New |
| Fortis Capital Advisors, LLC | 40,000 | $231.2K | 0.04% | +40,000 | New |
| Squarepoint Ops LLC | 40,173 | $232.2K | 0.00% | −18,922−32.0% | Reduced |
| BlackRock, Inc. | 40,379 | $233.4K | 0.00% | +2,223+5.8% | Added |
| Geode Capital Management, LLC | 64,551 | $373.1K | 0.00% | +39,075+153.4% | Added |
| Redmile Group, LLC | 82,955 | $479.5K | 0.05% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 112,751 | $651.7K | 0.00% | +16,000+16.5% | Added |
| Vanguard Group Inc | 203,051 | $1.17M | 0.00% | +73,212+56.4% | Added |
| Woodline Partners LP | 241,102 | $1.39M | 0.01% | +241,102 | New |
| Siren, L.L.C. | 318,264 | $1.84M | 0.07% | +35,678+12.6% | Added |
| Tang Capital Management LLC | 418,241 | $2.42M | 0.09% | +57,382+15.9% | Added |
| Samsara BioCapital, LLC | 11,448,081 | $66.2M | 8.64% | 00.0% | Unchanged |
| Octagon Capital Advisors LP | 0 | $0 | 0.00% | −360,000−100.0% | Sold out |
| Gilead Sciences, Inc. | 0 | $0 | 0.00% | −317,789−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −24,234−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −20,281−100.0% | Sold out |
| Raymond James Financial Inc | 0 | $0 | 0.00% | −2,629−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −2,153−100.0% | Sold out |